Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: testing Blood sampling for Cancer

The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process.

Official registry: https://clinicaltrials.gov/study/NCT04025541 · Institut du Cancer de Montpellier - Val d'Aurelle · enrollment listed as 992

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Blood sampling, Blood sampling C3, or Blood sampling C4/7/10/13. The registry lists allocation as randomized. The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades.

They plan to enroll about 992 people at 2 sites. Taking part typically means an infusion or injection of a biologic plus check-ins.

Official title (unrewritten)

Analysis of Circulating Tumor Markers in Blood

Interventions: Blood sampling, Blood sampling C3, Blood sampling C4/7/10/13, Blood sampling C5, Blood sampling C6, Blood sampling C8, Blood sampling C9, Blood sampling C11 + FFPE, Blood sampling C12

Primary outcome (registry wording): Estimation of the feasibility of the various blood tumoral biomarkers analysis

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
  • Man or woman ≥ 18 years,

Public study contact (from the registry)

texier emmannuelle

0467613102

emmanuelle.texier@icm.unicancer.fr

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

2 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Evaluation for NCI Surgery Branch Clinical Research Protocols

Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols.

NCT00001823 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

FAQ about this NCT record

Is NCT04025541 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT04025541?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT04025541?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary